Munich, Germany – GNH India, a WHO cGSDP-certified pharmaceutical wholesaler, made a significant impact at Expopharm 2016, Europe’s leading pharmaceutical trade fair, held from October 12–15 at Messe München. The event provided GNH India with a global stage to showcase its expertise in sourcing comparators and biosimilars, reinforcing India’s growing influence in the international pharmaceutical market.

Expopharm 2016 attracted thousands of industry professionals, including wholesalers, manufacturers, and distributors, to discuss trends, innovations, and challenges in the pharmaceutical sector. Dr. Piyush Gupta, Associate Director of Business Development at GNH India, presented the company’s capabilities in providing high-quality, cost-effective clinical trial supplies, with a focus on biosimilars and comparators sourced from India’s thriving biopharmaceutical ecosystem, which leads globally with nearly 100 approved biosimilars.

“Expopharm 2016 is a key opportunity for GNH India to connect with global partners and demonstrate how our WHO cGSDP-certified solutions meet the highest international standards,” said Dr. Gupta during the event.

GNH India highlighted its extensive network, covering over 180 countries, and a portfolio of more than 135,000 product lines. The company’s Mumbai-based facilities, compliant with GDP, GxP, and ISO standards, were showcased as a benchmark for reliability and precision in clinical trial supply chains. Attendees were particularly impressed by GNH India’s ability to reduce sourcing costs by up to 50% compared to traditional markets, while ensuring compliance with stringent global regulations.

The trade fair addressed critical topics such as supply chain optimization, regulatory compliance, and the growing role of biosimilars in global healthcare. GNH India’s smart sourcing strategies were presented as a solution to these challenges, enabling biopharmaceutical companies to streamline clinical trials without compromising quality. The event also facilitated new collaborations, with GNH India engaging with international stakeholders to expand its presence in the European market.

“India’s biosimilar expertise is transforming global clinical trials. At GNH India, we are committed to delivering affordable, high-quality solutions to our partners worldwide,” Dr. Gupta added.

GNH India’s participation in Expopharm 2016 underscored its role as a trusted partner in the global biopharmaceutical industry. With the biosimilars market projected to reach $12 billion by 2025, GNH India is well-positioned to meet the rising demand for cost-effective, compliant clinical trial supplies.